6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid | 890129-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid
• 英文别名: 6-(2-Amino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid；6-(2-aminopyrimidin-4-yl)oxynaphthalene-1-carboxylic acid
• CAS: 890129-77-8
• 化学式: C₁₅H₁₁N₃O₃
• 分子量: 281.271
• InChiKey: VFTMUBRDBGFXFE-UHFFFAOYSA-N

物化性质

• 沸点：
  607.5±53.0 °C(Predicted)
• 密度：
  1.439±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid 在 吡啶 、 4-二甲氨基吡啶 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 6-(2-methanesulfonylamino-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (4-fluoro-3-trifluoromethyl-phenyl)-amide
  参考文献：
  名称：

  WO2007/104538

  摘要：

  公开号：
• 作为产物：
  描述：

  6-羟基-1-萘甲酸 在 palladium 10% on activated carbon 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 40.0h， 生成 6-(2-amino-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid
  参考文献：
  名称：

  A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis

  摘要：

  This paper describes the identification of 6-(pyrimidin-4-yloxy)-naphthalene-1-carboxamides as a new class of potent and selective human vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitors. In biochemical and cellular assays, the compounds exhibit single-digit nanomolar potency toward VEGFR2. Compounds of this series show good exposure in rodents when dosed orally. They potently inhibit VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor vasculature as demonstrated by ELISA for TIE-2 in lysates or by immunohistochemical analysis. This novel series of compounds shows a potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role.

  DOI：

  10.1021/acs.jmedchem.5b01582

文献信息

• Compounds and methods of use
  申请人：Potashman Michele

  公开号：US20060241115A1

  公开（公告）日：2006-10-26

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗HGF介导的疾病等具有有效性。本发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐，以及用于预防和治疗涉及癌症等疾病和其他疾病或状况的药物组合物和方法。该发明还涉及制备此类化合物的过程，以及在此类过程中有用的中间体。
• Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
  申请人：Bold Guido

  公开号：US20100029626A1

  公开（公告）日：2010-02-04

  The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.

  本发明涉及公式（I）的新化合物及其在动物或人体治疗中的应用，包括含有公式（I）化合物的制药组合物，以及使用公式（I）化合物制备用于治疗蛋白激酶依赖性疾病的制药组合物，特别是增殖性疾病，如特定的肿瘤疾病。
• HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
  申请人：BOLD Guido

  公开号：US20120122857A1

  公开（公告）日：2012-05-17

  The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.

  本发明涉及公式（I）的新化合物及其在动物或人体治疗中的应用，包括含有公式（I）化合物的制药组合物，以及用于制备用于治疗蛋白激酶依赖性疾病的制药组合物的公式（I）化合物的使用，特别是增殖性疾病，如特定的肿瘤疾病。
• Heterobicyclic carboxamides as inhibitors for kinases
  申请人：Novartis AG

  公开号：US08133886B2

  公开（公告）日：2012-03-13

  The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumor diseases.

  本发明涉及一种新的公式(I)化合物及其在动物或人体治疗中的应用，包括含有公式(I)化合物的药物组合物，以及利用公式(I)化合物制备药物组合物，用于治疗蛋白激酶依赖性疾病，特别是增殖性疾病，如特定的肿瘤疾病。
• Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor
  申请人：Novartis AG

  公开号：EP2574340A2

  公开（公告）日：2013-04-03

  The invention provides a pharmaceutical combination: a) a pryrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor and a method for treating or preventing a proliferative disease using such a combination.

  本发明提供了一种药物组合：a) 一种丙烯酰氨基苯甲酰胺化合物，和 b) 一种 Thr315lle 激酶抑制剂，以及使用这种组合治疗或预防增殖性疾病的方法。